OTCMKTS:HBPCF

Helix BioPharma Stock Forecast, Price & News

$0.72
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.72
Now: $0.72
$0.72
50-Day Range
$0.59
MA: $0.66
$0.73
52-Week Range
$0.22
Now: $0.72
$1.15
VolumeN/A
Average Volume1,844 shs
Market Capitalization$101.62 million
P/E RatioN/A
Dividend YieldN/A
Beta0.04
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Helix BioPharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HBPCF
CUSIPN/A
CIKN/A
Phone905-841-2300
Employees10
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.02 per share

Profitability

Net Income$-6,680,000.00

Miscellaneous

Market Cap$101.62 million
Next Earnings Date7/29/2021 (Estimated)
OptionableNot Optionable

Headlines

HBP.TO: LDOS006 New Sites Open
April 5, 2021 |  finance.yahoo.com
Helix BioPharma Corp. (OTCMKTS:HBPCF) Short Interest Update
March 29, 2021 |  americanbankingnews.com
Helix Biopharma Corp. Responds to Market Activity
January 13, 2021 |  finance.yahoo.com
HBP.TO: Polish Subsidiary Definitive Sale
November 30, 2020 |  finance.yahoo.com
HBP.TO: Helix BioPharma Announces 3Q:20 Results
August 10, 2020 |  finance.yahoo.com
HBP.TO: Pancreatic Trial Enrolling
April 6, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1667th out of 2,011 stocks

Pharmaceutical Preparations Industry

690th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.72
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HBPCF News and Ratings via Email

Sign-up to receive the latest news and ratings for HBPCF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Helix BioPharma (OTCMKTS:HBPCF) Frequently Asked Questions

What stocks does MarketBeat like better than Helix BioPharma?

Wall Street analysts have given Helix BioPharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Helix BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Helix BioPharma?

Helix BioPharma saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 600 shares, a drop of 40.0% from the February 28th total of 1,000 shares. Based on an average trading volume of 7,700 shares, the days-to-cover ratio is currently 0.1 days.
View Helix BioPharma's Short Interest
.

When is Helix BioPharma's next earnings date?

Helix BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Helix BioPharma
.

How has Helix BioPharma's stock been impacted by Coronavirus?

Helix BioPharma's stock was trading at $0.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HBPCF shares have decreased by 25.8% and is now trading at $0.72.
View which stocks have been most impacted by COVID-19
.

Who are Helix BioPharma's key executives?

Helix BioPharma's management team includes the following people:
  • Dr. Heman Chao, CEO, Chief Scientific Officer, Member of Scientific & Strategic Advisory Board and Director (Age 58, Pay $239.02k)
  • Mr. Photios Michalargias C.A., CPA, CPA, CA, Chief Financial Officer (Age 58, Pay $226.66k)
  • Mr. Pawel Wisniewski, Chief Exec. Officer of Poland

Who are some of Helix BioPharma's key competitors?

What is Helix BioPharma's stock symbol?

Helix BioPharma trades on the OTCMKTS under the ticker symbol "HBPCF."

How do I buy shares of Helix BioPharma?

Shares of HBPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Helix BioPharma's stock price today?

One share of HBPCF stock can currently be purchased for approximately $0.72.

How much money does Helix BioPharma make?

Helix BioPharma has a market capitalization of $101.62 million.

How many employees does Helix BioPharma have?

Helix BioPharma employs 10 workers across the globe.

What is Helix BioPharma's official website?

The official website for Helix BioPharma is www.helixbiopharma.com.

Where are Helix BioPharma's headquarters?

Helix BioPharma is headquartered at 9120 Leslie Street Suite 205, Richmond Hill A6, L4B3J9.

How can I contact Helix BioPharma?

Helix BioPharma's mailing address is 9120 Leslie Street Suite 205, Richmond Hill A6, L4B3J9. The company can be reached via phone at 905-841-2300 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.